A non-inferiority study evaluating a new extended-release preparation of tilmicosin injected subcutaneously vs. ceftiofur administered intramammary, as dry-cow therapy in Holstein Friesian cows.
Animals
Cattle
Female
Anti-Bacterial Agents
/ administration & dosage
Cattle Diseases
/ drug therapy
Cephalosporins
/ administration & dosage
Delayed-Action Preparations
/ administration & dosage
Escherichia coli
/ drug effects
Escherichia coli Infections
/ drug therapy
Injections, Subcutaneous
/ veterinary
Mastitis, Bovine
/ drug therapy
Staphylococcal Infections
/ drug therapy
Staphylococcus aureus
/ drug effects
Streptococcal Infections
/ drug therapy
Streptococcus
/ drug effects
Tylosin
/ administration & dosage
Mastitis, bovine
ceftiofur
dry-cow therapy
long-acting tilmicosin
non-inferiority
Journal
Journal of veterinary science
ISSN: 1976-555X
Titre abrégé: J Vet Sci
Pays: Korea (South)
ID NLM: 100964185
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
27
08
2020
revised:
11
09
2020
accepted:
25
09
2020
entrez:
2
12
2020
pubmed:
3
12
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
A new, extended long-acting tilmicosin (TLAe) preparation was tested against intramammary ceftiofur (CEF) using a non-inferiority trial model during dry-cow therapy (DCT) in a farm with high bovine population density and deficient hygiene application. To evaluate the possibility that TLAe administered parenterally can achieve non-inferiority status compared to CEF administered intramammary for DCT. Cows were randomly assigned to TLAe (20 mg/kg subcutaneous; n = 53) or CEF (CEF-HCl, 125 mg/quarter; n = 38 cows) treatment groups. California mastitis testing, colony-forming unit assessment (CFU/mL), and number of cases positive for TLAe and CEF had overall cure rates of 57% and 53% ( This study is the first successful report of parenteral DCT showing comparable efficacy as CEF, the gold-standard. The extended long-term pharmacokinetic activity of TLAe explains these results.
Sections du résumé
BACKGROUND
BACKGROUND
A new, extended long-acting tilmicosin (TLAe) preparation was tested against intramammary ceftiofur (CEF) using a non-inferiority trial model during dry-cow therapy (DCT) in a farm with high bovine population density and deficient hygiene application.
OBJECTIVES
OBJECTIVE
To evaluate the possibility that TLAe administered parenterally can achieve non-inferiority status compared to CEF administered intramammary for DCT.
METHODS
METHODS
Cows were randomly assigned to TLAe (20 mg/kg subcutaneous; n = 53) or CEF (CEF-HCl, 125 mg/quarter; n = 38 cows) treatment groups. California mastitis testing, colony-forming unit assessment (CFU/mL), and number of cases positive for
RESULTS
RESULTS
TLAe and CEF had overall cure rates of 57% and 53% (
CONCLUSIONS
CONCLUSIONS
This study is the first successful report of parenteral DCT showing comparable efficacy as CEF, the gold-standard. The extended long-term pharmacokinetic activity of TLAe explains these results.
Identifiants
pubmed: 33263234
pii: 21.e87
doi: 10.4142/jvs.2020.21.e87
pmc: PMC7710465
doi:
Substances chimiques
Anti-Bacterial Agents
0
ceftiofur
83JL932I1C
Cephalosporins
0
Delayed-Action Preparations
0
tilmicosin
XL4103X2E3
Tylosin
YEF4JXN031
Types de publication
Journal Article
Randomized Controlled Trial, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
e87Subventions
Organisme : Consejo Nacional de Ciencia y Tecnología
ID : PAPIIT- UNAM IT201116
Pays : Mexico
Informations de copyright
© 2020 The Korean Society of Veterinary Science.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests. The National Autonomous University of Mexico (UNAM), owner of the patent, is open to licensing the novel preparation of the long-acting tilmicosin in test outside Mexico.
Références
J Dairy Sci. 1969 May;52(5):689-95
pubmed: 5391702
J Dairy Sci. 2001 Dec;84(12):2649-63
pubmed: 11814021
J Dairy Sci. 2011 Jan;94(1):250-61
pubmed: 21183035
Vet Clin North Am Food Anim Pract. 2012 Jul;28(2):203-16
pubmed: 22664203
Am J Vet Res. 2016 Sep;77(9):922-30
pubmed: 27580103
mBio. 2013 Feb 12;4(1):e00537-12
pubmed: 23404398
J Vet Pharmacol Ther. 2006 Aug;29(4):237-41
pubmed: 16846460
J Dairy Sci. 1999 Mar;82(3):645-7
pubmed: 10194686
J Vet Pharmacol Ther. 2018 Feb;41(1):22-27
pubmed: 28600854
Vet Clin North Am Food Anim Pract. 2003 Mar;19(1):109-38, vi
pubmed: 12682938
J Dairy Sci. 1969 May;52(5):696-707
pubmed: 5391057
J Dairy Sci. 2007 Aug;90(8):3764-76
pubmed: 17638988
J Dairy Sci. 1994 Jan;77(1):75-9
pubmed: 8120207
J Dairy Sci. 1999 Apr;82(4):696-703
pubmed: 10212455
Can J Comp Med. 1974 Oct;38(4):411-6
pubmed: 4279760
J Dairy Sci. 2007 Feb;90(2):779-89
pubmed: 17235155
Adv Drug Deliv Rev. 2001 Sep 1;50(3):245-59
pubmed: 11500230
J Dairy Sci. 1975 Dec;58(12):1828-35
pubmed: 1206136
J Dairy Sci. 2003 Jan;86(1):159-68
pubmed: 12613861
Am J Vet Res. 1988 Nov;49(11):1789-93
pubmed: 3073674
Zentralbl Veterinarmed B. 1999 Sep;46(7):433-42
pubmed: 10528539
Prev Vet Med. 2007 Mar 17;78(3-4):274-85
pubmed: 17137660
J Dairy Sci. 2016 Jan;99(1):593-607
pubmed: 26585471
J Dairy Sci. 1999 Jun;82(6):1202-12
pubmed: 10386306
J Dairy Sci. 1986 Jun;69(6):1721-32
pubmed: 3528249
Pharm Stat. 2016 Jan-Feb;15(1):80-9
pubmed: 26604186
J Dairy Sci. 2006 Jun;89(6):1877-95
pubmed: 16702252
J Dairy Sci. 2002 Jan;85(1):112-21
pubmed: 11860103
J Vet Pharmacol Ther. 1995 Oct;18(5):340-5
pubmed: 8587151
Vet Q. 2002 Dec;24(4):181-98
pubmed: 12540135